ROSETTA GENOMICS (ROSG)

REHOVOT, Israel and JERSEY CITY, New Jersey, September 5
/PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), a leader in
the development of microRNA-based diagnostic and therapeutic products,
announced today that the results of a study conducted by its scientists
describing the identification of microRNA biomarkers in blood serum, have
been published online in the peer-reviewed journal PLOS One. The findings
demonstrate that microRNAs have the potential to be used as clinical
biomarkers for a wide range of indications in cancer and women's health.

Using its proprietary extraction and quantification methods, Rosetta
Genomics is now advancing the development of a blood-based test which will
utilize microRNAs to detect patients with colon cancer.

"This study further validates our understanding that microRNAs may be
used as clinical biomarkers for a wide range of indications, both through
invasive and non-invasive methods," noted Dr. Dalia Cohen, Chief Scientific
Officer of Rosetta Genomics. "The results of this study are the basis of one
of our development programs to detect colon cancer via microRNAs identified
in serum. I believe our strong scientific capabilities will continue to
produce exciting studies, which we will share once available."

The paper, "Serum MicroRNAs are Promising Novel Biomarkers" is now
available on PLOS One website on
http://dx.plos.org/10.1371/journal.pone.0003148

About microRNAs

MicroRNAs (miRNAs) are recently discovered, naturally occurring, small
RNAs that act as master regulators and have the potential to form the basis
for a new class of diagnostics and therapeutics. MicroRNAs have been shown to
have different expression profiles in various pathological conditions. As a
result, these differences may provide for a novel diagnostic strategy for
many diseases.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA.
Founded in 2000, the company's integrative research platform combining
bioinformatics and state-of-the-art laboratory processes has led to the
discovery of hundreds of biologically validated novel human microRNAs.
Building on its strong IP position and proprietary platform technologies,
Rosetta Genomics is working on the application of these technologies in the
development of a full range of microRNA-based diagnostic and therapeutic
tools, focusing primarily on cancer and various women's health indications.
The first test based on the company's technology, differentiating squamous
from non squamous non small cell lung cancer, is now approved through
Columbia University Medical Center's High Complexity Molecular Pathology
Laboratory. In Addition, the company expects two additional microRNA
diagnostic tests applying its technology will be validated and submitted for
regulatory approval by licensed clinical laboratories in the United States in
2008.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future
expectations, plans and prospects, including without limitation, statements
relating to the potential of microRNAs extracted from blood to serve as
effective biomarkers for a wide range of indications, including colon cancer,
the role of microRNAs in human physiology and disease, the potential of
microRNAs in the diagnosis and treatment of disease, and the timing of launch
of the first diagnostic tests applying Rosetta's microRNA technology
constitute forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of 1995. Actual
results may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including risks related
to: Rosetta's approach to discover and develop novel diagnostics and
therapeutic tools, which is unproven and may never lead to marketable
products or services; Rosetta's ability to fund and the results of further
pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and
protect the intellectual property utilized by Rosetta's products; Rosetta's
ability to enforce its patents against infringers and to defend its patent
portfolio against challenges from third parties; Rosetta's ability to obtain
additional funding to support its business activities; Rosetta's dependence
on third parties for development, manufacture, marketing, sales, and
distribution of products; Rosetta's ability to successfully develop its
candidate tools, products and services, all of which are in early stages of
development; Rosetta's ability to obtain regulatory clearances or approvals
that may be required for its products and services; the ability to obtain
coverage and adequate payment from health insurers for the products and
services comprising Rosetta's technology; competition from others using
technology similar to Rosetta's and others developing products for similar
uses; Rosetta's dependence on collaborators; and Rosetta's short operating
history; as well as those risks more fully discussed in the "Risk Factors"
section of Rosetta's Annual Report on Form 20-F for the year ended December
31, 2007 as filed with the Securities and Exchange Commission. In addition,
any forward-looking statements represent Rosetta's views only as of the date
of this release and should not be relied upon as representing its views as of
any subsequent date. Rosetta does not assume any obligation to update any
forward-looking statements unless required by law.

SOURCE Rosetta Genomics Ltd